Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-12-2015 | Editorial

Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks

Authors: A. Pfestroff, M. Luster, C. A. Jilg, P. J. Olbert, C. H. Ohlmann, M. Lassmann, H. R. Maecke, S. Ezziddin, L. Bodei, on behalf of the Radionuclide Therapy Committee of the European Association of Nuclear Medicine

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 13/2015

Excerpt

Prostate cancer (PCA), the second most common cancer in men and the fourth most common malignancy overall, causes an estimated 90,000 deaths per year in Europe [1]. Castration-resistant PCA (CRPC) is defined according to the Prostate Cancer Working Group 2 criteria as PCA with any progression occurring in the presence of castrate-level testosterone values. This progression may be biochemical, i.e. a rise in prostate-specific antigen (PSA) levels, or clinical, i.e. appearance of metastases on imaging [2]. …

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi:10.1002/ijc.29210.CrossRefPubMed

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59. doi:10.1200/JCO.2007.12.4487.PubMedCentralCrossRefPubMed

Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. doi:10.1056/NEJMoa041318.CrossRefPubMed

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. doi:10.1056/NEJMoa040720.CrossRefPubMed

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54. doi:10.1016/S0140-6736(10)61389-X.CrossRefPubMed

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi:10.1056/NEJMoa1014618.PubMedCentralCrossRefPubMed

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60. doi:10.1016/S1470-2045(14)71205-7.CrossRefPubMed

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97. doi:10.1056/NEJMoa1207506.CrossRefPubMed

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33. doi:10.1056/NEJMoa1405095.PubMedCentralCrossRefPubMed

10.

Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23. doi:10.1056/NEJMoa1213755.CrossRefPubMed

11.

West TA, Kiely BE, Stockler MR. Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials. Eur J Cancer. 2014;50:1916–24. doi:10.1016/j.ejca.2014.04.004.

12.

Jadvar H. PSMA PET in prostate cancer. J Nucl Med. 2015;56:1131–2. doi:10.2967/jnumed.115.157339.CrossRefPubMed

13.

Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284–94. doi:10.1007/s00259-015-3078-6.CrossRefPubMed

14.

Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182–91. doi:10.1158/1078-0432.CCR-13-0231.PubMedCentralCrossRefPubMed

15.

Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76. doi:10.2967/jnumed.115.158550.CrossRefPubMed

16.

Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, et al. A phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clin Cancer Res. 2015. doi:10.1158/1078-0432.CCR-15-0552.PubMed

17.

Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504–17. doi:10.1021/jm800111u.PubMedCentralCrossRefPubMed

18.

Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74. doi:10.2967/jnumed.115.154153.CrossRefPubMed

19.

Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68:530–4. doi:10.1016/j.eururo.2015.04.034.CrossRefPubMed

20.

Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97. doi:10.1021/bc200279b.CrossRefPubMed

21.

Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20. doi:10.2967/jnumed.114.147413.CrossRefPubMed

22.

Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114. doi:10.1186/s13550-015-0114-2.PubMed

23.

Kratochwil C, Giesel FL, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H, et al. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med. 2015;56:293–8. doi:10.2967/jnumed.114.147181.CrossRefPubMed

24.

Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565–74. doi:10.1007/s11307-015-0850-8.PubMedCentralCrossRefPubMed

25.

Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855–61. doi:10.2967/jnumed.115.156133.CrossRefPubMed

26.

Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280–92. doi:10.1007/s00259-014-2713-y.PubMedCentralCrossRefPubMed

27.

Kabasakal L, AbuQbeitah M, Aygun A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-015-3125-3.PubMed

28.

Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, et al. MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53:1310–25. doi:10.2967/jnumed.111.100123.PubMedCentralCrossRefPubMed

29.

Lassmann M, Eberlein U. Radiation dosimetry aspects of (177)Lu. Curr Radiopharm. 2015;8:139–44.CrossRefPubMed

Title: Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks
Authors: A. Pfestroff
M. Luster
C. A. Jilg
P. J. Olbert
C. H. Ohlmann
M. Lassmann
H. R. Maecke
S. Ezziddin
L. Bodei
on behalf of the Radionuclide Therapy Committee of the European Association of Nuclear Medicine
Publication date: 01-12-2015
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 13/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3186-3

At a glance: The STEP trials

Springer Medicine

Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 13/2015

18 F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases

Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer

The use of SPECT/CT for anatomical mapping of lymphatic drainage in vulvar cancer: possible implications for the extent of inguinal lymph node dissection

Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients

Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment?

Prognostic role of metabolic parameters of 18F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma